Zobrazeno 1 - 10
of 296
pro vyhledávání: '"Ivana N. Micallef"'
Autor:
Luis F. Porrata, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Jose C. Villasboas, Jonas Paludo, Urshila Durani, Svetomir N. Markovic
Publikováno v:
Biomedicines, Vol 12, Iss 8, p 1808 (2024)
The infusion autograft absolute number of inhibitory killer immunoglobulin-like receptor (KIR) 2DL2 and activating natural killer (NK)p30 cells are predictors of clinical outcomes in lymphoma patients undergoing autologous peripheral blood hematopoie
Externí odkaz:
https://doaj.org/article/b3a97a241f6841a1a9597a51a9d7c2aa
Autor:
Charlotte B. Wagner, Ken Boucher, Adrienne Nedved, Ivana N. Micallef, Sanjal Desai, Haris Hatic, Gaurav Goyal, Erin Zacholski, Amanda Fegley, Audrey M. Sigmund, David A. Bond, Courtney Samuels, Manali K. Kamdar, Sheeba Ba Aqeel, Pallawi Torka, Kira MacDougall, Azra Borogovac, Sridevi Rajeeve, Suchitra Sundaram, Kalub Fedak, Dipenkumar Modi, Elizabeth Travers, Sabarish Ayyappan, Nitin Chilakamarri, Elizabeth A. Brem, Daniel A. Ermann, Lindsey A. Fitzgerald, Boyu Hu, Deborah M. Stephens, Harsh Shah
Publikováno v:
Haematologica, Vol 108, Iss 11 (2023)
Sixteen cycles of Brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in high-risk relapsed/refractory classical Hodgkin lymphoma demonstrated an improved 2-year progression-free survival (PFS) over placebo. However, most patients a
Externí odkaz:
https://doaj.org/article/551d8a1644b244c18b60306f73172409
Autor:
Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Jose C. Villasboas, Jonas Paludo, Svetomir N. Markovic
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 488-491 (2022)
Abstract Our phase III trial reported that autograft‐absolute lymphocyte count (A‐ALC) improved survival post‐autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) for a short‐term follow‐up of 2 years. We evaluated
Externí odkaz:
https://doaj.org/article/45ba8ace3f8141bdabdf7603913ad971
Autor:
Karan L. Chohan, Jason R. Young, Scott Lester, Muhamad Alhaj Moustafa, Allison Rosenthal, Han W. Tun, Bradford S. Hoppe, Patrick B. Johnston, Ivana N. Micallef, Thomas M. Habermann, Stephen M. Ansell
Publikováno v:
Haematologica, Vol 108, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/0faa280edcc44a2d880b62ef0cb9fae2
Autor:
Jennifer J. Gile, Camden L. Lopez, Gordon J. Ruan, Matthew A. Hathcock, Jithma P. Abeykoon, Joy R. Heimgartner, Nikola A. Baumann, M. Molly McMahon, Ivana N. Micallef, Patrick B. Johnston, Jose C. Villasboas Bisneto, Luis F. Porrata, Jonas Paludo, Stephen M. Ansell, William J. Hogan, Thomas E. Witzig
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-9 (2021)
Abstract Magnesium is an essential element that is involved in critical metabolic pathways. A diet deficient in magnesium is associated with an increased risk of developing cancer. Few studies have reported whether a serum magnesium level below the r
Externí odkaz:
https://doaj.org/article/64d895b86c3842b0b58e9bd4963c7186
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma
Autor:
Luis F. Porrata, Kay Ristow, Joseph P. Colgan, Thomas M. Habermann, Thomas E. Witzig, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Grzegorz S. Nowakowski, Carrie Thompson, Svetomir N. Markovic
Publikováno v:
Haematologica, Vol 97, Iss 2 (2012)
Background Lymphopenia and tumor-associated macrophages are negative prognostic factors for survival in classical Hodgkin’s lymphoma. We, therefore, studied whether the peripheral blood absolute lymphocyte count/absolute monocyte count ratio at dia
Externí odkaz:
https://doaj.org/article/14e83c2a1cd64f5d964aa8d5d69b1c0a
Autor:
Luis F. Porrata, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Stephen M. Ansell, William J. Hogan, Svetomir N. Markovic
Publikováno v:
Clinical and Developmental Immunology, Vol 2010 (2010)
Natural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). The potent
Externí odkaz:
https://doaj.org/article/ecdfedebd0814c48a11ce1c9e90cdc8c
Autor:
Sanjal H. Desai, Michael A. Spinner, Kevin David, Veronika Bachanova, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacques Azzi, Vaishalee P. Kenkre, Sally Arai, Cheryl Chang, Brendon Fusco, Nuttavut Sumransub, Haris Hatic, Raya Saba, Uroosa Ibrahim, Elyse I. Harris, Harsh Shah, Jacob Murphy, Stephen Ansell, Deepa Jagadish, Victor Orellana‐noia, Catherine Diefenbach, Siddharth Iyenger, K. C. Rappazzo, Rahul Mishra, Yun Choi, Grzegorz S. Nowakowski, Ranjana H. Advani, Ivana N. Micallef
Publikováno v:
American Journal of Hematology. 98:464-471
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1dac0e9a4298c037371c2a8e6fc45bc9
https://doi.org/10.1002/ajh.26827
https://doi.org/10.1002/ajh.26827
Autor:
Darragh F. O'Donoghue, Huong L. Truong, Heidi D. Finnes, Jennifer S. McDonald, Heather P. May, Stephen M. Ansell, N. Nora Bennani, Thomas M. Habermann, David J. Inwards, Patrick B. Johnston, Arushi Khurana, Yi Lin, Ivana N. Micallef, Grzegorz S. Nowakowski, Jonas Paludo, Luis F. Porrata, Gita Thanarajasingam, Carrie A. Thompson, Jose C. Villasboas, Yucai Wang, Thomas E. Witzig, Nelson Leung
Publikováno v:
JCO Oncology Practice. 18:e1908-e1917
PURPOSE: High-dose methotrexate (HDMTX; > 500 mg/m2) is an important component of lymphoma therapy. Serum MTX monitoring at 48 hours is the standard approach to identify those at increased risk of developing MTX toxicity. Our aim was to characterize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::422d8b68ff67e79d35280ba6853a5943
https://doi.org/10.1200/op.22.00182
https://doi.org/10.1200/op.22.00182
Autor:
Mohamed A. Kharfan-Dabaja, Luis F. Porrata, Jose Villasboas Bisneto, Hemant S. Murthy, Ivana N. Micallef, Ernesto Ayala, Muhamad Alhaj Moustafa, Allison C. Rosenthal, Zhuo Li, Han W. Tun, Patrick B. Johnston, Yennifer Gil Castano, Stephen M. Ansell, Madiha Iqbal, David J. Inwards, James M. Foran, Manuel Beltran, Jonas Paludo, Vivek Roy, Craig B. Reeder
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e89-e95
Germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) at diagnosis is associated with superior long-term outcomes compared to non-GCB-DLBCL in patients treated with conventional chemo-immunotherapy. Whether cell of origin (COO) by Han
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2088385fcb42ea2bf6614456d87c6862
https://doi.org/10.1016/j.clml.2021.08.011
https://doi.org/10.1016/j.clml.2021.08.011